Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors
- 作者:Venkata K. Pokuri ; Mei Ka Fong ; Renuka Iyer
- 关键词:Octreotide ; Lanreotide ; Synthetic ; Somatostatin ; Gastroenteropancreatic ; Neuroendocrine tumors ; Cost ; analysis
- 刊名:Current Oncology Reports
- 出版年:2016
- 出版时间:January 2016
- 年:2016
- 卷:18
- 期:1
- 全文大小:310 KB
- 参考文献:1.Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRef PubMed
2.Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1–18. vii.CrossRef
3.Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–63.CrossRef PubMed
4.Frilling A, Akerstrom G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19(5):R163–85.CrossRef PubMed
5.Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbeck’s Arch Surg. 2011;396(3):273–98.CrossRef
6.Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014;28(9):749–56. 758.
7.Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47 Suppl 2:30–9.CrossRef PubMed
8.Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.CrossRef PubMed
9.••
Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33. This is the phase 3 study establishing the anti-proliferative activity of Lanreotide, resulting in FDA approval of the first synthetic somatostatin analog for antitumor activity in gastro-entero-pancreatic neuroendocrine tumors.CrossRef PubMed
10.Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology. 2004;80 Suppl 1:57–61.PubMed
11.Meier RF, Reichert MM. Octreotide: a clinical update. Saudi J Gastroenterol. 1998;4(3):147–55.PubMed
12.Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246–54.CrossRef PubMed
13.Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–98.CrossRef PubMed
14.Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–6.CrossRef PubMed
15.Astruc B, Marbach P, Bouterfa H, et al. Long-acting
octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45(7):836–44.CrossRef PubMed
16.Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous
octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600–6.PubMed
17.••
Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose
octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015;21(6):1945–55. This is a systematic review of all the studies which utilized higher than conventional doses of Octreotide LAR formulation. Despite wide use of these higher doses in clinical practice, there are no large, randomized trials proving their superiority over conventional doses of Octreotide LAR. This review summarizes the benefit of higher dose Octreotide LAR in carcinoid symptom control along with its antitumor efficacy.PubMedCentral CrossRef PubMed
18.Woltering EA, Mamikunian PM, Zietz S, et al. Effect of
octreotide LAR dose and weight on
octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31(4):392–400.CrossRef PubMed
19.Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39(2):279–83.PubMedCentral CrossRef PubMed
20.Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–88.PubMed
21.O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus
octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770–6.CrossRef PubMed
22.Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87(1):99–104.CrossRef PubMed
23.Lightman S. Somatuline autogel: an extended release lanreotide formulation. Hosp Med. 2002;63(3):162–5.CrossRef PubMed
24.Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer. 2006;107(10):2474–81.CrossRef PubMed
25.Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34(2):235–42.CrossRef PubMed
26.Ruszniewski PCM, Valle J. Patient-reported satisfaction with symptom control during lanreotide Autogel/Depot treatment for carcinoid syndrome in gastroenteropancreatic neuroendocrine tumor patients: SymNET, a large multinational cross-sectional observational study. GI Cancers Symposium. 2014. Abstract No: 273.
27.Vinik AWE, Audry H. ELECT: a phase III study of efficacy and safety of lanreotide Autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs). GI Cancers Symposium. 2014. Abstract No: 268.
28.Strosberg JR, Fisher GA, Benson AB, et al. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas. 2013;42(3):397–404.CrossRef PubMed
29.Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006;66(3):1576–82.CrossRef PubMed
30.Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16(24):2963–70.PubMedCentral CrossRef PubMed
31.Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13:822–40.CrossRef PubMed
32.Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17(6):747–55.PubMedCentral CrossRef PubMed
33.Arnold RWM, Rinke A, Schade-Brittinger C, Aminossadati B. E R. Placebo controlled, double blind, prospective, randomized study on the effect of
octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long-term survival. Proc Am Soc Clin Oncol. 2013;31. Abstr: 4030.
34.••
Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. This article provides the guidelines (NANETS, North American Neuro Endocrine Tumor Society and NCCN, National Comprehensive Cancer Network) in the management of neuroendocrine tumors (NETs). Apart from identifying the applicability of synthetic somatostatin analogs in NETs, it also describe various other modalities of treatment for NETs and furnish guidelines to be used in day to day clinical practice.